Adjunctive administration of tirofiban during primary percutaneous coronary intervention is associated with enhanced myocardial tissue perfusion and improved left ventricular functional recovery in patients with ST-segment elevation myocardial infarction, according to a retrospective evaluation. The investigation, conducted by researchers at Zhangjiakou First Hospital in Hebei, China, examined patients presenting with ST-segment elevation myocardial infarction who underwent urgent catheter-based revascularization. By combining conventional angiographic evaluations with advanced three-dimensional echocardiography and laboratory biomarker assays, the clinical team analyzed whether adding tirofiban to standard primary percutaneous coronary intervention provided measurable microvascular and functional benefits over mechanical intervention alone.
The retrospective analysis initially reviewed medical records from 114 eligible patients diagnosed with ST-segment elevation myocardial infarction who were treated with primary percutaneous coronary intervention between March 2024 and May 2025. Among the overall cohort, 61 individuals had undergone coronary intervention alone, whereas 53 patients had received adjunctive tirofiban alongside the standard catheter procedure. To minimize selection bias and balance baseline characteristics between the two treatment strategies, the investigators implemented a one-to-one propensity score matching protocol. This matching procedure successfully produced 48 matched pairs, establishing a balanced cohort of 96 patients whose general baseline data exhibited no statistically significant differences between the two treatment arms, thereby confirming the comparability of the cohorts before comparing subsequent clinical trajectories.
To evaluate myocardial recovery with high anatomical and functional precision, the investigators employed complementary diagnostic modalities focusing on both tissue-level microvascular blood flow and global ventricular performance. Myocardial perfusion was assessed using angiographic myocardial blush grade. Concurrently, left ventricular functional recovery was quantified by capturing three-dimensional echocardiographic full-volume datasets, which were subsequently analyzed offline using TomTec computational software to establish left ventricular ejection fraction. Before treatment, baseline values for myocardial blush grade and left ventricular ejection fraction demonstrated statistical comparability across both groups with P-values greater than 0.05, confirming equivalent initial degrees of circulatory and myocardial compromise.
Following therapeutic intervention, both patient cohorts exhibited demonstrable changes from their pre-procedure baselines, but the magnitude of recovery was significantly greater among patients who received adjunctive tirofiban. In post-treatment assessments, the myocardial blush grade reached an average score of 2.42 ± 1.02 in the tirofiban group compared with 1.58 ± 0.88 in the control group, representing a statistically significant difference with a between-group P-value of less than 0.001. Parallel gains were documented in systolic function, as three-dimensional echocardiographic analysis revealed that left ventricular ejection fraction rose to 55.74 ± 3.12 percent in the tirofiban-treated cohort compared to 48.89 ± 5.17 percent in the conventional intervention cohort, also achieving statistical significance at a P-value of less than 0.001 for between-group comparisons of changes.
Baseline concentrations of cardiac troponin I, superoxide dismutase, and endothelin had been comparable between the two groups prior to treatment, and both arms showed significant changes after therapy. However, post-treatment levels of cardiac troponin I, a highly specific marker of ongoing myocardial injury, were significantly lower in patients receiving adjunctive tirofiban than in those managed with intervention alone, averaging 12.34 ± 1.76 compared to 16.73 ± 1.98. Furthermore, the treatment group showed greater improvements in superoxide dismutase levels than the control group (P < 0.001). The treatment group also showed greater improvements in endothelin levels than the control group (P < 0.001).
The research team systematically tracked major adverse cardiac events, a composite clinical endpoint encompassing cardiac death, recurrent myocardial infarction, hospital admission for worsening heart failure, and unplanned target-vessel revascularization.
Subject of Research: Adjunctive tirofiban during primary percutaneous coronary intervention for myocardial infarction
Article Title: Effects of adjunctive tirofiban during PCI on myocardial perfusion and ventricular function in myocardial infarction: a 3D echocardiography-based evaluation
Article References: Wang, X., Han, Y., & Zhang, C. (2026). Effects of adjunctive tirofiban during PCI on myocardial perfusion and ventricular function in myocardial infarction: a 3D echocardiography-based evaluation. Frontiers in Cardiovascular Medicine, 13, Article 1857341. https://doi.org/10.3389/fcvm.2026.1857341
Image Credits: AI Generated
DOI: 10.3389/fcvm.2026.1857341
Keywords: Tirofiban, Percutaneous coronary intervention, Myocardial infarction, STEMI, Three-dimensional echocardiography, Myocardial blush grade, Left ventricular ejection fraction, Propensity score matching, Effects, adjunctive, during, myocardial
News Source: Ophelia Keating. (November 10, 2026). Adjunctive Tirofiban Associated With Improved Myocardial Perfusion and Ventricular Function in STEMI. Scienmag.



